Labcorp to expand bioanalytical services with integrated laboratory in Singapore

BURLINGTON, N.C. --(BUSINESS WIRE)--May 19, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced the expansion of its drug development offering in the Asia-Pacific region with the addition of bioanalytical services in Singapore.

A customized scaffolds approach for the detection and phasing of complex variants by next-generation sequencing

Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity

The impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis

High-throughput Citrate Quantification by NMR in the Clinical Laboratory

Geographic and Temporal Mapping of the SARS-CoV-2 Pandemic in the United States